Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Inclusion Criteria: * Histologically confirmed solid tumors, including CNS tumors or lymphoma * Histological confirmation not required for the following diagnoses * Intrinsic brain stem tumors * Optic pathway gliomas * Pineal tumors and elevations of cerebral spinal fluid or serum tumor markers, including alpha-fetoprotein or beta-human chorionic gonadotropin, allowed * Relapsed or refractory disease * Must have measurable or evaluable tumor * No known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Karnofsky performance status (PS) 60-100% for patients \> 16 years of age OR Lansky PS60-100% for patients ≤ 16 years of age * Neurologic deficits inpatients with CNS tumors must have been relatively stable for a minimum of 1week * Patients who are unable to walk because ofparalysis, but who are up in a wheelchair, will be considered ambulatory for thepurpose of assessing the performance score * ANC ≥ 1,000/μL * Platelet count ≥ 100,000/μL (transfusion independent, defined as not receiving platelet transfusions within the past 7 days) * Patients with known bone marrow metastatic disease allowed provided they meet the blood count criteria and are not known to be refractory to platelet transfusion * Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions) * Patients with known bone marrow metastatic disease allowed provided they meet the blood count criteria and are not know to be refractory to RBC or platelet t…